PDCD1 and central nervous system cancer: Nonetheless, using this strategy, we found that T cell proliferation could not be increased ex vivo via anti-PD1 treatment in glioma samples (zero of seven), while in BrM, we observed a proliferation increase following anti-PD1 treatment in three of ten samples (Fig. 5h and Extended Data Fig. 6d).